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Abstract: 18 
Ureaplasma are associated with numerous clinical sequelae with treatment options being limited due 19 
to patient and pathogen factors.  This report examines the prevalence and mechanisms of antibiotic 20 
resistance among clinical strains isolated from 95 neonates, 32 women attending sexual health clinic 21 
and 3 patients under investigation for immunological disorders, between 2007 – 2013 in England and 22 
Wales. Minimum inhibitory concentration was determined by using microbroth dilution assays, and a 23 
subset of isolates were compared using broth microdilution method and Mycoplasma-IST2 assay.  24 
The underlying molecular mechanisms for resistance were determined for all resistant isolates.  Three 25 
isolates carried the tet(M) tetracycline resistance gene (2.3% CI+2.58); two isolates were 26 
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ciprofloxacin resistant (1.5% CI+2.09) but sensitive to levofloxacin and moxifloxacin, while no 27 
resistance was seen to any macrolides tested.  MIC values for chloramphenicol were universally low 28 
(2 µg/mL), while inherently high level MIC values for gentamicin were seen (44-66 µg/mL).  The 29 
Mycoplasma-IST2 assay identified a number of false-positives for ciprofloxacin resistance as the 30 
method does not conform to international testing guidelines.  While antibiotic resistance among 31 
Ureaplasma isolates remains low, continued surveillance is essential to monitor trends and threats 32 
from importation of resistant clones. 33 
 34 
Introduction: 35 
Ureaplasma spp. are gaining recognition as a pathogen in both adult and neonatal patient groups.  36 
Availability of standardized molecular detection methods have increased the capacity to identify 37 
Ureaplasma in pathological conditions, which was previously difficult to identify by specialized 38 
culture-based methods. In adults Ureaplasma have been linked with non-gonococcal urethritis, 39 
arthritis, meningitis, chorioamnionitis and preterm labour whereas in neonates links have been made 40 
with bronchopulmonary dysplasia, neonatal pneumonia and meningitis (5, 6, 12, 18, 20, 22). 41 
  42 
Upon diagnosis of infection, treatment options are limited for a number of reasons.  The absence of a 43 
bacterial cell wall renders Ureaplasma spp. intrinsically resistant to all beta-lactam and glycopeptide 44 
antibiotics.  The three classes of antibiotic which are recognized as active against ureaplasma are the 45 
quinolones, tetracyclines and macrolides.  These treatment options are further limited in situations 46 
with neonates where the only recognized treatment is with a macrolide due to associated toxicity of 47 
the tetracyclines and quinolones (13). 48 
 49 
Although two human associated Ureaplasma species have been recognized since 2002, Ureaplasma 50 
urealyticum and Ureaplasma parvum, many diagnostic laboratories still do not differentiate and report 51 
findings as U. urealyticum by default (16).  This lack of discrimination hinders epidemiological data 52 
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and has partly been accountable for the lack of understanding and potential varied pathogenicity of the 53 
two species.  A recent systemic review and meta-analysis by Zhang et al., has supported the idea of U. 54 
urealyticum contributing to the development of  non-gonococcal urethritis (NGU) whereas U. parvum 55 
does not (25).  These data suggest that U. urealyticum may be a true pathogen in this situation 56 
whereas U. parvum represents a commensal.     57 
 58 
In this report we describe the prevalence of antibiotic resistance among isolates of Ureaplasma from 59 
England and Wales in addition to the mechanisms of resistance.  We also include susceptibility testing 60 
for Ureaplasma spp. against chloramphenicol and gentamicin, which do not act on the cell wall but on 61 
the ribosome as the mechanism of action.  62 
 63 
Materials and Methods: 64 
Clinical samples 65 
A total of 130 clinical Ureaplasma spp. isolates from anonymized unique patient samples originally 66 
submitted for clinical diagnostics between 2007 and 2013 were examined (Table 1).  Species of 67 
Ureaplasma was determined by PCR as previously described (19). Sample source comprised a variety 68 
of patient groups: 61 neonatal endotracheal samples (15 U. urealyticum / 46 U. parvum) from Public 69 
Health England reference laboratory, 32 cervical samples (5 U. urealyticum / 27 U. parvum) from 70 
private sexual health patients, 18 neonatal endotracheal samples (4 U. urealyticum / 14 U. parvum) 71 
from University Hospital of Wales, 16 neonatal endotracheal samples (4 U. urealyticum / 12 U. 72 
parvum) from Derriford Hospital and 3 urine samples from patients with immune deficiencies from 73 
University Hospital of Wales (U. parvum). 74 
 75 
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Determination of antibiotic resistance with broth microdilution and 76 
Mycoplasma-IST2 77 
Determination of minimum inhibitory concentration (MIC) and breakpoints were carried out as 78 
previously described by Beeton et al.,(4) which adheres to the Clinical and Laboratory Standards 79 
Institute guidelines (21).  Antibiotics used for MIC were tetracycline, doxycycline, ciprofloxacin, 80 
levofloxacin, moxifloxacin, erythromycin, azithromycin, clarithromycin, chloramphenicol and 81 
gentamicin at a range of 0.06 µg/mL to 64 µg/mL.  Antibiotics were purchased from Sigma-Aldrich 82 
(Dorset, UK) and Ureaplasma selective media (USM) was supplied by Mycoplasma Experience Ltd 83 
(Surrey, UK).  Twenty clinical samples submitted for testing to the Public Health England laboratory 84 
were examined in parallel to standard methods with the Mycoplasma-IST2 (bioMérieux, France) 85 
assay as per the manufacturer’s instructions; eight were found to be positive for Ureaplasma spp. and 86 
identified resistance for ciprofloxacin for all isolates was followed up by appropriate broth 87 
microdilution methods. 88 
 89 
PCR and sequencing of resistance genes 90 
PCR and sequencing of the quinolone resistance-determining region (QRDR) of ciprofloxacin 91 
resistant strains was carried out as previously described and aligned to the U. parvum SV3 reference 92 
genome of ATCC 700970 (2, 3).  Confirmation of the tet(M) gene in tetracycline resistant strains was 93 
determined by PCR using the forward primer IntMtet1  located at position 309-328 bp and reverse 94 
primer tet2  located at position 832-851 bp in the coding region (Tm=55oC, 35 cycles, amplicon = 543 95 
bp). Extended sequencing of the tet(M) gene was accomplished using the tetMF-78 and tetM-R_2123 96 
primers.  All primers have been previously published.(4, 8)    97 
 98 
5 
 
Statistical analysis 99 
Statistics for the mean, standard deviation, standard error, and confidence intervals for MIC values for 100 
U. parvum and U. urealyticum were determined using GraphPad Prism and comparison of values 101 
between these species was performed via Students t-test. 102 
 103 
 104 
Results: 105 
Prevalence of resistance 106 
Using the adapted broth microdilution technique we were able to identify two isolates resistant to 107 
ciprofloxacin (U6 32 µg/mL and HPA116 16 µg/mL), and three isolates which were tetracycline 108 
resistant (Table 2).  This gave a prevalence of resistance of 1.5% (CI + 2.09) and 2.3% (CI + 2.58), 109 
respectively, for each antibiotic.  No breakpoint values for resistance of ciprofloxacin are available in 110 
the CLSI guidelines (20); however, published breakpoints for moxifloxacin and levofloxacin indicate 111 
resistance to be ≥ 4 µg/mL.  Both strains U6 and HPA116 were more sensitive to moxifloxacin (1 112 
µg/mL) and levofloxacin (2 µg/mL) (Table 2), but these values were still higher than our susceptible 113 
strains: ≤0.25 µg/mL for moxifloxacin and ≤0.5 µg/mL for levofloxacin (data not shown).  All 130 114 
isolates were sensitive to the macrolide antibiotics erythromycin and azithromycin as well as 115 
chloramphenicol. All strains had an intrinsically high MIC for gentamicin(MIC90 values of 64 µg/mL 116 
for U. parvum and 128 µg/mL for U. urealyticum) . No co-resistant strains were identified.  The mean 117 
MIC of all antibiotics was significantly higher for U. urealyticum than U. parvum with exception of 118 
chloramphenicol and azithromycin (Table 3). 119 
 120 
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Screening for tetracycline resistance gene 121 
Tetracycline resistance is well characterized among Ureaplasma species and is associated with the 122 
presence of the horizontally acquired tet(M) resistance gene. We screened DNA isolated from all 123 
isolates by PCR for the presence of the tet(M) gene and identified three positive strains of the 130 124 
isolates (Table 4). Interestingly, broth culture screening for tetracycline resistance only identified two 125 
of these isolates (HPA111, MIC = 64 and Ply157, MIC = 8), while the third tet(M)-positive isolate 126 
was initially sensitive to tetracycline (HPA71 MIC = 1). However, subculture from the lowest sub-127 
inhibitory concentration of tetracycline found increased MIC for HPA111 (MIC >64) and Ply157 128 
(MIC=64), while HPA71 remained sensitive (MIC=2). A second serial challenge with tetracycline 129 
found that resistance had been induced for HPA71 (MIC=64).  This induction of resistance in HPA71 130 
was repeated twice with identical results.  Therefore, screening for the presence of the tet(M) gene is 131 
less likely to miss resistant isolates than microbroth dilution methods for tetracycline resistance.  We 132 
sequenced the 3’ region of the tet(M) gene for the three isolates identified as tet(M) positive (two 133 
phenotypically resistant, one initially phenotypically sensitive).  From this we identified that HPA71 134 
and HPA111 were most closely related to the previous Vancouver SV9 sequence, whereas Ply157 135 
was a chimera of both Vancouver and Seattle sequences (Table 4).  No mutations within the 3’ region 136 
were identified to explain the required induction of tetracycline resistance for HPA71 (accession 137 
number KT267561). Susceptibility to doxycycline was similar to that observed for tetracycline for the 138 
resistant isolates (Table 2).   139 
 140 
Molecular mechanism for ciprofloxacin resistance 141 
Molecular characterization was undertaken on two identified ciprofloxacin resistant isolates using 142 
previously described PCR-sequencing of the QRDR (2, 4).  Sequence analysis aligned to the 143 
published genome of U. parvum SV3 ATCC 700970 revealed two amino acid substitutions of V3D 144 
and E87K in ParC of isolate U6 and a S83L ParC substitution in isolate HPA116. 145 
 146 
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Identification of resistance using the MIST2 test 147 
The bioMérieux Mycoplasma IST2 kit was used to screen a subset of twenty submitted samples and 148 
the results for resistance to a spectrum of biologically active antibiotics.  From the 20 samples 149 
examined 8 were found to be Ureaplasma spp. positive and all gave a reading of resistance to both the 150 
lower (1 µg/mL) and higher (2 µg/mL) levels for ciprofloxacin.  The assay also showed that all 151 
Ureaplasma were able to grow in 1 µg/mL of ofloxacin, but not the higher 4 µg/mL concentration. 152 
However, using the accepted international MIC broth microdilution technique, repeated in duplicate, 153 
three of these ciprofloxacin isolates had an MIC = 1 µg/mL (identified as U. parvum), three had an 154 
MIC = 2 µg/mL (identified as U. parvum) and two had an MIC = 4 µg/mL (identified as U. 155 
urealyticum).  The microbroth dilution values determined that all of these isolates were sensitive to 156 
ciprofloxacin and consistent with the MIC90 for their respective species (Table 3).  157 
 158 
  159 
 160 
Discussion 161 
Over recent years ureaplasma have gained increasing recognition as a pathogen in numerous clinical 162 
presentations.  Due to physiological properties of the organism, and in some cases the patient 163 
population, treatment options are highly restricted to only a few classes of antibiotics.  Therefore it is 164 
imperative to monitor trends in resistance both England and Wales and at an international level so that 165 
treatment options remain open.  In this study we report that antibiotic resistance in England and Wales 166 
remains low to the three major classes of antibiotic used to treat Ureaplasma infections.  167 
 168 
We last reported antibiotic resistance in Ureaplasma among isolates in England and Wales for 169 
samples collected before 2007 (4).  At this point in time 1.6% of isolates collected in England and 170 
Wales between 2003 and 2007 were resistant to one of the three main classes of antibiotics and no 171 
dual resistance was identified.  Here from a larger cohort of 130 isolates we report a similar level of 172 
8 
 
resistance to ciprofloxacin (1.5%) and presence of the tetracycline resistance gene (2.3%), whereas 173 
macrolide resistance was absent.  This is a reassuringly low level of resistance when compared with 174 
international reports.  For example, Ye et al. reported 75% and 53% resistance to ciprofloxacin and 175 
ofloxacin, respectively (24).  High levels of tetracycline resistance (73%) have been documented in 176 
South African studies as well as high levels of azithromycin resistance (29%) among patient cohorts 177 
in India (10, 15).  This high level of macrolide resistance is of significant concern in the context of 178 
treating neonatal disease.  Although comparisons can be made between studies it is crucial to observe 179 
the methods used to detecting resistance.  For example Ye et al., used the Mycoplasma IST2 test, 180 
which from our data identified a number of false positive results with regards to ciprofloxacin when 181 
compared to the standardized microbroth dilution technique (24).  In addition the breakpoints and 182 
antibiotics used in this test are not in line with the recommended CLSI guidelines (20).  In particular 183 
the input inoculum for this assay is not standardized and cannot be measured by this assay, likely the 184 
cause of the false resistance results.  Of interest from our data was the MIC values seen for U. 185 
urealyticum were significantly higher when compared with U. parvum for most antibiotics tested.  As 186 
U. parvum and U. urealyticum are recognized as two independent species, this is not a surprising 187 
finding.   188 
 189 
Understanding the underlying mechanism of resistance is imperative. Sequence analysis of the 190 
QRDRs of isolate U6 identified two non-synonymous mutations resulting in the amino acid 191 
substitutions of V3D and E87K in ParC protein.  From our previous work cataloguing the species and 192 
serovar specific differences it is possible to definitively assign the E87K substitution to the 193 
phenotypic resistance (3).  This substitution has been noted before in France by Bebear et al., who 194 
reported isolate UUc with the E87K substitution with a ciprofloxacin and ofloxacin MIC of 8 µg/mL 195 
(1).  Interestingly although isolate U6 harbors the same point mutation as UUc, the MIC value was 4-196 
fold greater.  Previously the V3D substitution may have been classified as contributing to the resistant 197 
phenotype of U6, yet this substitution appears to be a serovar specific polymorphism whereby U. 198 
parvum SV3 and all serovars of U. urealyticum encode a valine residue, whereas serovars 1, 6 and 14 199 
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encode aspartic acid at position three for ParC, although this data is based on a limited number of 200 
sequenced isolates (3).  However, this observation has been further substantiated in our lab by 201 
examining whole genome sequences for three additional SV3 strains, two SV6 strains and one SV1 202 
strain (unpublished data).  Irrespective of serovar association (which may not hold as more sequences 203 
become available), the V3D substitution in ParC does not contribute to fluroquinolone resistance as it 204 
exists in susceptible strains. The second ciprofloxacin resistant strain (HPA116) was identified to 205 
harbor the predominant quinolone resistance determining mutation S83L.  This mutation has been 206 
described numerous times from patient cohorts from the USA, China, France and Switzerland, but this 207 
is the first description among UK isolates (1, 11, 17, 23, 26). As the mechanism for quinolone 208 
resistance is mutation driven and not horizontally transferred, the likelihood of spread is limited as it 209 
would be clonal and could account for the relatively low level of resistance within these organisms. 210 
 211 
Tetracycline resistance is well characterized among Ureaplasma and mediated via the acquisition of 212 
the tet(M) resistance element giving ribosomal protection (7).  As expected all tetracycline resistant 213 
strains in this study were positive for tet(M) in addition to a tetracycline sensitive isolate (HPA71).  214 
By characterizing tet(M) positive strains it is possible to track the emergence of new sequence 215 
variants within the UK.  From these data we identified two out of three tet(M) positive strains to be 216 
identical to the Vancouver sequence which we have previously described in the UK, but curiously the 217 
tet(M) sequence of isolate Ply157 was a chimera of both Vancouver and Seattle strains.  This is 218 
unlikely an artifact as it was confirmed by multiple sequencing experiments performed on this isolate.  219 
As with our study in 2009 we identified a single isolate which was tet(M) positive, but phenotypically 220 
sensitive to the antibiotic (HPA71).  We were successful in inducing expression and resultant 221 
resistance for this strain (but not other sensitive strains examined in parallel) with the presence of low 222 
levels of tetracycline in the culture medium.  This brings into question the methods used for screening 223 
tetracycline resistance among Ureaplasma.  When examining tetracycline resistance it may be 224 
necessary to screen by both culture and molecular methods to identify strains which harbor tet(M) 225 
variants which require induction via presence of the antibiotic.  The inducible nature of some tet(M) 226 
genes has been previously reported in Mycoplasma hominis, but this is the first description among 227 
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Ureaplasma (9).  From the three main classes of antibiotics active against Ureaplasma, tetracycline 228 
resistance poses a significant threat due to the horizontally transferable nature of the Tn916 like 229 
transposable element harboring the tet(M) gene and its potential to disseminate within a population. 230 
 231 
We also compared the commercial assay Mycoplasma-IST2 against the international broth 232 
microdilution methods as outlined by the Clinical and Laboratory Institute Standards (21).  We found 233 
that mixed isolation of Ureaplasma and Mycoplasma hominis of one sample showed as a false-234 
positive macrolide resistance due to the intrinsic macrolide resistance seen among M. hominis., and 235 
that all Ureaplasma positive samples were found to be resistant to the low (1 µg/mL) and high (2 236 
µg/mL) concentrations of ciprofloxacin provided in the kit (14).  However, broth microdilution 237 
evaluation of these found that three of the isolates had an MIC = 1 µg/ml and 3 of the isolates had an 238 
MIC = 2 µg/mL.  All of these isolates were U. parvum.  The remaining two isolates were U. 239 
urealyticum and had an MIC = 4 µg/mL which is within keeping with the slightly higher CI95 240 
determined to be between 2.64-3.66 µg/mL for ciprofloxacin.  Therefore, none of the isolates were 241 
actually resistant to ciprofloxacin, relative to normal sensitivity ranges for the organisms tested and 242 
questions the data obtained from this assay.  Moreover, it could lead to inappropriate reporting of 243 
antibiotic resistance if used by researchers without a clear understanding of the internationally 244 
accepted methods and criteria for true antibiotic resistance. 245 
 246 
Antibiotic resistance in England and Wales remains low.  The high levels of resistance internationally 247 
poses a threat of import into the UK and therefore continual surveillance is required to keep tract of 248 
resistance patterns. While it is tempting to attribute the continued low antibiotic resistance rates in the 249 
England and Wales to vigilance in keeping antibiotic prescription to a minimum, the geographic 250 
differential in antibiotic resistance is unlikely to be maintained, particularly with increasing travel 251 
between countries in combination with the increased prescribing of macrolide antibiotics for N. 252 
gonorrhoeae, Chlamydia trachomatis and Mycoplasma genitalium infections.  253 
 254 
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Table 1. Source and year of isolation for Ureaplasma species used for MIC determination. 366 
Source 2007 2008 2009 2010 2011 2012 2013 total 
PHE (PCR +) N/A N/A N/A 28 47 33 60 168 
PHE (PCR -) N/A N/A N/A 74 137 182 194 587 
PHE 
(recovered for 
MIC) 
8 19 19 10 5   61 
UHW (+) 7 2  2 3 3 1 18 
UHW (-) 17 6  2 2 4 9 40 
Plymouth (+)     2 8 6 16 
Plymouth (-)     19 20 10 49 
RGH (+)     3 20 9 32 
RGH (-)     6 36 15 57 
Urine (+)  1 2     3 
Urine (-)  3 6     9 
Legend: Samples were obtained from Public Health England (PHE), University Hospital of Wales 367 
neonatal intensive care unit (UHW) or immunological out-patients (Urine), Derriford Hospital 368 
neonatal intensive care unit (Plymouth) or the Royal Glamorgan Hospital (RGH).  Not all PHE isolates 369 
were recoverable from frozen archives for MIC determination. N/A = data not available. 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
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Table 2.  Overview of antibiotic resistant isolates identified from UK samples between 2007 to 2013. 378 
Isolate (year isolated) Species of 
Ureaplasma
Antibiotic resistance 
(MICµg/mL) 
Mechanism of 
resistance 
U6 (2009) U. parvum Ciprofloxacin (32) 
Levofloxacin (2) 
Moxifloxacin (1) 
E87K in ParC 
HPA116 (2013) U. parvum Ciprofloxacin (16) 
Levofloxacin (2) 
Moxifloxacin (1) 
S83L in ParC 
HPA111 (2008) U. urealyticum Tetracycline (64) 
Doxycycline (16) 
Tet(M) positive 
PLY157 (2013) U. parvum Tetracycline (8) 
Doxycycline (8) 
Tet(M) positive 
HPA71 (2007) U. urealyticum Tetracycline (64*) 
Doxycycline (16*) 
Tet(M) positive 
* MIC following challenge with tetracycline (initial MIC = 1µg/mL)  379 
  380 
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Table 3. Comparison of MIC50 and MIC90 concentrations of various antibiotics between U. parvum 381 
and U. urealyticum.    382 
 383 
Antibiotic Total 
Ureaplasma 
resistant 
U. parvum U. urealyticum p-value* 
MIC50 MIC90 MIC50 MIC90  
Tetracycline 3 0.25 0.5 0.5 2 <0.001 
Ciprofloxacin 2 1 2 2 4 <0.001 
Erythromycin 0 1 2 2 4 <0.003    
Azithromycin 0 0.25 0.25 0.25 0.25 ns 
Chloramphenic
ol 
0 2 4 2 4 ns 
Gentamicin 130 32 64 64 128 <0.01 
P-value represents a student’s t-test comparison of the individual MIC values for all U. parvum 384 
isolates compared to the MIC values for all U. urealyticum isolates. 385 
 386 
Table 4.  UK tet(M) positive isolates compared with reference strains at the amino acid level 387 
Isolate Amino acid position 
209 216 223 338 348 496 627 
Vancouver Q L S K T D Q 
Seattle H V N R I E R 
HPA71 Q L S K T D Q 
HPA111 Q L S K T D Q 
Ply157C H V N K T D Q 
 388 
